Table 1 Characteristics of included studies
Study | Country | Study design | Sample size (n) | Clinical scenario | Mean age (y) | Male/% | Follow-Up (m) | CI-AKI (%) | Type of PCI | Contrast volume/ml | CI-AKI Definition (after PCI) |
|---|---|---|---|---|---|---|---|---|---|---|---|
Sadeghi et al. 2003 [32] | USA | PC | 2082 | AMI | 59.3 | 73.3 | Max: 12 | 4.6 | primary | – | IScr ≥0.5 mg/dL within the index hospitalization (5.7 ± 3.5 days) |
Uyarel et al. 2009 [37] | Turkey | RC | 2521 | STEMI | 56.5 | 82.9 | Median: 21 | 25.0 | primary | 237.0 | IScr ≥0.5 mg/dl or 25% within 72 h |
Wickenbrock et al. 2009 [12] | Germany | PC | 392 | STEMI 51.8% NSTEMI 48.2% | 64 | 71.4 | During hospitalization | 11.5 | primary | 234.9 | IScr > 0.5 mg/dl within 72 h |
Akkaya et al. 2011 [13] | Turkey | RC | 2486 | STEMI | 56.4 | 83.3 | Median: 21 | 24.4 | primary | 236.3 | IScr ≥0.5 mg/dl or 25% within 72 h |
Chong et al. 2011 [33] | Singapore | RC | 3822 | NSTEMI 36.1% UA 63.9% | 57.1 | 78.1 | Max: 6 | 8.4 | elective | – | IScr ≥0.5 mg/dl or 25% within 48 h |
Wi et al. 2013 [47] | Finland | PC | 1041 | STEMI 49% NSTEMI 51% | 62.7 | 72.0 | Mean: 22.8 Max: 24 | 14.2 | elective | 219 | IScr > 0.5 mg/dL or 25% within 48 h when no other major kidney insult |
Kume et al. 2013 [18] | Japan | RC | 194 | STEMI | 68.1 | 66.5 | Mean: 36 | 11.9 | primary | 172.7 | IScr > 0.5 mg/dl or 50% within 48 h |
Lucreziotti et al. 2014 [14] | Italy | PC | 323 | STEMI | 65.3 | 71.5 | Median: 18 Max: 29.7 | 15.2 | primary | 259 | IScr ≥0.5 mg/dl or 25% during the first 3 post-procedural days. |
Narula et al. 2014 [19] | USA | PC | 2968 | STEMI | 60.4 | 76.5 | Max: 36 | 16.1 | primary | 228.2 | IScr ≥0.5 mg/dL or 25% within 48 h |
Watabe et al. 2014 [22] | Japan | RC | 1059 | STEMI 56.7% NSTEMI 15.3% UA 28.0% | 69.0 | 76.3 | Mean: 14.5 | 15.5 | primary | 184.2 | IScr ≥0.5 mg/dL or 25% within 1 week |
Akin et al. 2015 [15] | Turkey | RC | 630 | STEMI | 56.7 | 81.0 | During hospitalization | 12.5 | primary | 143.3 | IScr ≥0.3 mg/dL within 48 h |
Cicek et al. 2015 [16] | Turkey | PC | 645 | STEMI | 56.5 | 85.3 | Max: 6 | 13.6 | primary | 233.3 | IScr > 0.5 mg/dL or 25% within 48 h |
Crimi et al. 2015 [34] | Italy | PC | 1443 | STE-ACS 44.9% NSTE-ACS 55.1% | – | – | Mean: 22.8 Median: 24 | 10.8 | N/A | – | IScr ≥25% |
Giacoppo et al. 2015 [24] | USA | PC | 9512 | ACS | 62.5 | 72.3 | Max: 12 | 12.7 | primary | 221.5 | IScr ≥0.5 mg/dL or 25% within 72 h |
Turan et al. 2015 [26] | Turkey | RC | 312 | NSTEMI | 59 | 76.0 | Mean: 38 Max: 40 | 9.6 | elective | 154.8 | IScr > 0.5 mg/dl or 25% within 72 h |
Centola et al. 2016 [35] | Italy | RC | 402 | STEMI | 64.9 | 72.0 | Median: 12 | 17.4 | primary | 257.4 | IScr ≥0.5 mg/dl or 25% within72h |
Farhan et al. 2016 [36] | Austria | PC | 536 | STEMI 35.5% NSTEMI 47.0% UA 17.5% | 62.7 | 68.1 | Mean: 94 Max: 108.9 | 9.5 | N/A | 255.4 | RIFLE/AKIN criteria |
Gungor et al. 2016 [25] | Turkey | RC | 587 | STEMI | 56.0 | 66.1 | Median: 12 Max: 24 | 21.8 | primary | 163.2 | IScr ≥0.5 mg/dL or 25% within 72 h |
Kuboyama et al. 2016 [27] | Japan | PC | 247 | STEMI | 66.7 | 76.5 | Mean: 31.2 | 27.1 | primary | 152.1 | IScr ≥0.5 mg/dL or 25% within 72 h |
Nakahashi et al. 2016 [20] | Japan | RC | 577 | STEMI | 64.4 | 78.7 | Max: 36 | 35.7 | primary | 168.5 | IScr ≥0.5 mg/dL or 25% within 72 h |
Park et al. 2016 [23] | Korea | PC | 668 | STEMI | 61.3 | 77.2 | Mean: 26.4 | 10.9 | primary | – | IScr ≥0.5 mg/dL or 25% within 48 h |
Park et al. 2016(2) [17] | Korea | PC | 334 | STEMI | 62.7 | 79.3 | During hospitalization | 21.6 | primary | 159.8 | IScr ≥0.5 mg/dL or 25% within 72 h |